Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott publishes positive trial data for psoriasis treatment

Abbott publishes positive trial data for psoriasis treatment

13th October 2010

Abbott has revealed new clinical trial results which illustrate the potential benefits of a new treatment for sufferers of moderate to severe chronic plaque psoriasis.

The company has published data from four separate phase III clinical studies of briakinumab at the recent European Association of Dermatology and Venereology scientific sessions.

According to the findings, Abbott's drug delivered better skin clearance rates than two alternative drug therapies, as well as a placebo control group.

The drug functions by targeting the IL-12/23 proteins linked to inflammation, as opposed to other commonly-prescribed psoriasis treatments that target the tumour necrosis factor (TNF) protein.

Dr Eugene Sun, vice-president for global pharmaceutical development at Abbott, said: "While anti-TNFs are the cornerstone of biologic treatment for psoriasis, this data suggests that briakinumab may be evaluated as a potentially important alternative treatment option for some psoriasis patients."

Earlier this month, Abbott was named as one of the top 20 employers in the biotechnology and pharmaceutical sector by readers of industry publication Science Magazine.ADNFCR-8000103-ID-800113250-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.